Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces FDA Acceptance of the Company's First New Drug Application for Ryaltris for Patients with Seasonal Allergic Rhinitis08-08-2018
08-08-2018
Glenmark Pharmaceuticals' Partner Elite Pharmaceuticals Receives US FDA Approval For Generic Methadone Hydrochloride Tablets
We wish to inform you that Glenmark's partner Elite Pharmaceuticals, Inc., a US specialty pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) for methadone hydrochloride 5 mg and 10 mg tablets. Methadone is indicated for the management of pain severe enough to require daily, around-the-clock long-term opioid treatment and for which alternative treatment...07-08-2018
Glenmark in deal with Chinese firm Harbour BioMed for innovative molecule
With a stringent regulatory environment in China, not many Indian companies have been able to conduct clinical trials in that market07-08-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers06-08-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, August 13, 2018 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.02-08-2018
Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, August 10, 2018, inter alia, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2018....30-07-2018
Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2018.
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2018 ,inter alias, to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30, 2018. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors...30-07-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals Announces Encouraging Phase 1 Results Supporting Biosimilarity Criteria for GBR 310 Compared to the Reference Product Omalizumab26-07-2018
Shareholding for the Period Ended June 30, 2018
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here17-07-2018
Glenmark Pharmaceuticals to file appeal before NCLAT against CCI penalties
Drug firm Glenmark Pharmaceuticals today said it will file an appeal against the order of the Competition Commission of India (CCI) before the National Company Law Appellate Tribunal. On July 13, CCI had imposed penalties totalling nearly Rs 47 crore on Glenmark Pharmaceuticals, its three officials, two other pharma companies and four Gujarat-based chemists associations for indulging in unfair business practices. Besides, a carry and forward (C&F) agent had also been penalised. M/s Reliance Medical Agency had filed a complaint with the CCI against the Chemist & Druggist Association of Baroda including pharma companies and C&F agents alleging that prior to being appointed as stockist they were required to obtain NOC from the local Chemist and Druggist Associations in Gujarat, Glenmark said in a BSE filing. "The Commission has relied on findings of the Director General and held that Glenmark is mandating no-objection certificates (NOC) from the trade associations for...17-07-2018